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In vitro SUSCEPTIBILITY TESTING OF DERMATOPHYTES ISOLATED FROM PEDIATRIC
CASES IN NIGERIA AGAINST FIVE ANTIFUNGALS
E.I. NWEZE(1, 2), C.C. OGBONNA(3) & J.I. OKAFOR(1)
SUMMARY
The antifungal activities of itraconazole, ketoconazole, fluconazole, terbinafine and griseofulvin were tested by broth
microdilution methods against 71 isolates of dermatophytes isolated from Nigerian children. Most drugs were very active against
all the dermatophytes and the MIC 90 ranged from 0.03 to 8.0 µg/mL. This appears to be the first documented data on the
antifungal susceptibility testing of isolates of dermatophytes from Nigerian children.
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INTRODUCTION
Dermatophytosis is a common cutaneous fungal disease caused by
species belonging to the genera Trichophyton, Microsporum and
Epidermophyton. Several therapeutic regimens are reported to have
activity in these fungi and are therefore being used in treating it9,17.
Although in the last few years, there has been a steady introduction of
new drugs by either modification of pre-existing or entirely new
chemical classes of antimycotics, there has also been an increased
interest in clinically relevant susceptibility testing16 . This has become
necessary due to a considerable increase in the prevalence of
dermatophytoses all over the world especially in underdeveloped
countries such as Nigeria2,8,13,14 among the elderly and in
immunocompromised patients6. It is known that there is lack of data
on the antifungal susceptibility of dermatophytes in African countries,
such as Nigeria, where the occurrence of dermatophytosis is endemic.
Expansion of information on in vitro susceptibility testing of
dermatophytes will provide data that will help in developing or selecting
drug regimens10. In addition, the various cases of imported
dermatophyte infection across different countries and their variable
response to the antifungals make exchange of information on
susceptibility data across different countries necessary. Therefore, the
purpose of the present work was to carry out antifungal susceptibility
testing on clinical isolates from pediatric cases of dermatophytosis.
MATERIALS AND METHODS
Test isolates: A total of seventy-one isolates of dermatophytes were
evaluated. Out of this 27 were Trichophyton tonsurans, 15 were
Trichophyton soudanense, seven were Trichophyton violaceum, five
were Trichophyton rubrum, four were Trichophyton verrucosum, nine
were Trichophyton mentagrophytes, three were Trichophyton
schoenlenii and two each of Epidermophyton flocossum and
Microsporum audounii. Three American Typed Culture Collections
(ATCC) quality control organisms were used: Candida parasilopsis
ATCC 22019, Trichophyton mentagrophytes (ATCC 40004) and
Candida krusei ATCC 6258. These dermatophytes were mainly isolates
from different body sites collected during previous investigational study
13,14
. The cultures were maintained on Saboraud dextrose agar slants
supplemented with cycloheximide, chloramphenicol and genticin
(SAB-CCG). Freshly growing cultures on SAB-CCG slants were
transferred to oatmeal agar slants two weeks prior to the study to
enhance conidial production as proposed previously12.
Antifungal agents: Five antifungal agents were used, itraconazole
(ITR) and ketoconazole (KET) (Jansen), fluconazole (FLU) (Pfizer),
terbinafine (TER), (Novartis) and griseofulvin (GRI) (Schering Plough).
Fluconazole and ketoconazole were dissolved in sterile distilled water
while the rest were dissolved in 100% dimethylsulphuroxide (Sigma-
Aldrich). They were subsequently prepared as stock solutions and stored
at appropriate temperature.
In vitro tests for susceptibility: For susceptibility testing, the drugs
were diluted in RPMI 1640 (Sigma-Aldrich) with L-glutamine but
without sodium bicarbonate and buffered at PH 7 with MOPS.
Preparation of inocula: The inocula were prepared according to
NORRIS et al.12. Briefly, conidial suspensions of dermatophytes
prepared from seven to fourteen day old culture grown on oatmeal
cereal agar slants were made. The slants were flooded with 0.85%
sterile saline and swabbed with a cotton wool tip applicator. The
resulting mixture of conidia and hyphal particles were subsequently
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transferred to a sterile tube. After settling for about 15-20 minutes, the
upper layer (about 2 mL) of the suspension was removed and adjusted
for 80-85% transmission using a colorimeter. This corresponds to an
inoculum of 1-5 x 106
 
CFU/mL. The inoculum was adjusted to 5 mL
with saline (0.85%) and diluted further in RPMI 1640 to achieve a
final concentration of 2-5 x 103 CFU/mL.
Testing procedure: The procedure followed CLSI guideline M
27-P11, Micro dilution plates were set up and each test plate had two
drug free growth controls, one with the media alone (growth control)
and the other with media containing an equivalent amount of solvent
used to dissolve the antifungal drug (solvent control). The plates (two
for each) were incubated at 30 0C and 35 0C respectively and read
visually after four and five days of incubation. Growth was normally
checked after 48 h post inoculation. Endpoint determinations were
made by visually comparing the growth in the wells containing the
drug with the growth in the solvent control well. MIC ranges were
obtained for each species-drugs combination tested. To facilitate
comparisons of the activities of the drugs, the MIC was reported as the
concentration at which 50% (MIC50) and 90% (MIC90) of the isolates
were inhibited.
RESULTS
The in vitro susceptibilities of 71 isolates of dermatophytes to
terbinafine, itraconazole, ketoconazole, fluconazole and griseofulvin
are summarized in Table 1. The MIC90 and MIC50 are also shown.
The data are presented as MIC ranges and, where appropriate, as the
drug concentrations required to inhibit 50 and 90% of the isolate of
each species (MIC90 and MIC50 respectively) All the 71 isolates of
dermatophytes tested were susceptible to the five antifungal drugs used
in the study. The MIC of all the quality control strains used were within
established ranges (data not shown)1.
Although detectable growths were noticed after four days of
incubation in some cases, majority of the isolates had pronounced
growth after five days. We observed no major differences in incubating
at 30 or 35 °C, but our result reflect readings recorded at 35 0C. However,
no resistance was recorded among all the isolates. The isolates were
less susceptible for griseofulvin and fluconazole with MICs ranging
from 0.125 - 16.0 and 0.25 - 64 µg/mL. The MIC90 range for them
respectively is between 2.0 - 8.0 µg/mL for griseofulvin and 4.0 - 16.0
µg/mL for fluconazole. Terbinafine was the most effective drug against
all isolates of dermatophytes since the MIC90 range was between 0.01
- 0.07 µg/mL. The order of in vitro activity is therefore terbinafine >
itraconazole > ketoconazole > griseofulvin > fluconazole.
DISCUSSION
 Monitoring antimicrobial resistance is useful because apart from
tracking and detection of resistance trends by microorganisms, it also
gives clues to emerging threats of new resistance. This serves among
other things, in assessing interventional efforts and empirical treatments
recommendations15. In the past, several authors have performed in vitro
susceptibility tests on various strains of dermatophytes6,10,12 . However,
there is a scarcity of data on susceptibility studies of isolates from the
West African sub region like Nigeria13,14. Therefore, this is the first large-
scale in vitro susceptibility testing of dermatophytes obtained from
Table 1
MICs of the five drugs against seventy-one clinical isolates of dermatophytes.
MIC (µg/mL)
Species (nA) Antifungal Range MIC50B MIC90
drug
T. tonsurans(25) TER 0.007-0.125 0.07 0.125
ITR 0.06-0.5000 0.01 0.03
KET 0.125-1.00 0.125 0.25
FLU 0.25-16.00 1.00 4.00
GRI 0.50-16.00 2.00 8.00
T. soundanense(15) TER 0.01-0.25 0.01 0.06
ITR 0.03-0.125 0.03 0.125
KET 1.00-16.00 1.00 2.00
FLU 8.00-32.00 8.00 16.00
GRI 2.00-16.00 2.00 8.00
T. mentagrophytes TER 0.007-0.500 0.07 -
(9) ITR 0.01-4.00 0.01 -
KET 0.06-4.00 0.05 -
FLU 0.06-64.00 2.00 -
GRI 0.125-4.00 0.50 -
T. violaceum (7) TER 0.007-0.125 0.01 -
ITR 0.01-1.00 0.01 -
KET 0.03-0.25 0.25 -
FLU 1.00-8.00 1.00 -
GRI 0.25-8.00 0.50 -
T. verrucosum(4) TER 0.007-0.125 0.007 -
ITR 0.125-1.00 0.125 -
KET 1.00-16.00 2.00 -
FLU 4.00-16.00 4.00 -
GRI 0.50-4.00 4.00 -
T. rubrum(5) TER 0.03-0.25 0.007 -
ITR 0.03-1.00 0.03 -
KET 0.125-4.00 0.125 -
FLU 1.00-8.00 2.00 -
T. schoenleinii(3) TER 0.007 - -
ITR 0.01-0.50 - -
KET 0.06-0.125 - -
FLU >16 - -
GRI 4.00-16.00 - -
M. audouinii(2) TER 0.01 - -
ITR 0.01-0.125 - -
KET 0.01-0.50 - -
FLU 0.50-2.00 - -
GRI 0.25-1.00 - -
E. floccosum(2) TER 0.01-0.125 - -
ITR 0.01-0.50 - -
KET 0.01-1.00 - -
FLU 0.50-2.00 - -
GRI 1.00-2.00 - -
nA: number of isolates tested; B: MIC for 50% of the isolates tested; -: MIC 50 and
90 were not determined because of their small sample number.
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Nigeria pediatric patients, against a wide range of commonly used
antifungals in our country. Like we have noted above, we observed no
major differences in the MIC endpoints by incubating at 30 0C or 35 0C.
Information available in the literature from other authors10,15,16 indicated
that four days of incubation were sufficient to observe noticeable growth
in the control wells. We therefore recorded our MIC values after four
days of incubation. However, our results disagreed from SANTOS &
HAMADA18 and from FERNANDEZ-TORRES et al.5 . In another study
FERNANDEZ-TORRES et al.4 tested 508 strains belonging to 24 species
of dermatophytes against conventional (itraconazole and fluconazole)
and some newer antifungal agents like voriconazole and UR-9825, with
similar results. This seems to support the fact that incubating for four or
seven days does not have a significant effect on the MIC readings.
Nevertheless, our result on terbinafine as the most active agent for
example, agrees with the observation from previous authors in other
continents and region5,18. This antimycotic showed an excellent in vitro
potency and broad-spectrum activity against all the tested species. This
suggests that terbinafine can be used to treat a majority of dermatophytic
infections especially those showing high MIC values on the azoles,
such as fluconazole. Although we did not include the newer antifungals
such as posaconazole, voriconazole etc in our study, we noticed in
literature, their promising antifungal activities. In Nigeria, these
antifungals are relatively new and not readily available, affordable and
widely used as the ones we have tested. This buttresses our initial
observation that most patients with dermatophytoses resort to use of
some medicinal plants as a preferred treatment choice apparently due
to inability to afford the orthodox drugs14.
It will be of interest to state that all isolates used in our study were
obtained from patients not previously on any antifungal treatment.
Interestingly, there was no record of resistance in our study even though
some agents recorded high MIC values than others. From our data,
ketoconazole appears to be the next choice in terms of in vitro activity
after terbinafine and itraconazole. This information among other things
will assist clinicians to monitor trend and be able to choose effective
medications for treating patients with dermatophytoses, especially in
countries like Nigeria where dermatophytoses have become a public
health problem and have remained endemic13.
RESUMO
Teste de susceptibilidade in vitro de dermatófitos isolados de
casos pediátricos na Nigéria contra cinco antifúngicos
Atividades antifúngicas de itraconazole, ketoconazole, fluconazole,
terbinafine e griseofulvina foram testadas por métodos de microdiluição
em caldo contra 71 isolados de dermatófitos de crianças nigerianas. A
maioria das drogas foi muito ativa contra todos os dermatófitos e o
MIC 90 variou de 0,03 a 8,0 µg/mL.  Estes parecem ser os primeiros
dados documentados sobre os testes de susceptibilidade antifúngica
de isolados de dermatófitos de crianças nigerianas.
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